147 related articles for article (PubMed ID: 14516794)
1. Ets2 is not required for Ras or Neu/ErbB-2 mediated cellular transformation in vitro.
Hevér A; Oshima RG; Hauser CA
Exp Cell Res; 2003 Oct; 290(1):132-43. PubMed ID: 14516794
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation.
Galang CK; García-Ramírez J; Solski PA; Westwick JK; Der CJ; Neznanov NN; Oshima RG; Hauser CA
J Biol Chem; 1996 Apr; 271(14):7992-8. PubMed ID: 8626480
[TBL] [Abstract][Full Text] [Related]
3. Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness.
Foos G; Hauser CA
Oncogene; 2000 Nov; 19(48):5507-16. PubMed ID: 11114728
[TBL] [Abstract][Full Text] [Related]
4. Elevated expression of Ets2 or distinct portions of Ets2 can reverse Ras-mediated cellular transformation.
Foos G; García-Ramírez JJ; Galang CK; Hauser CA
J Biol Chem; 1998 Jul; 273(30):18871-80. PubMed ID: 9668063
[TBL] [Abstract][Full Text] [Related]
5. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2.
Yang BS; Hauser CA; Henkel G; Colman MS; Van Beveren C; Stacey KJ; Hume DA; Maki RA; Ostrowski MC
Mol Cell Biol; 1996 Feb; 16(2):538-47. PubMed ID: 8552081
[TBL] [Abstract][Full Text] [Related]
6. The her-2/neu oncogene stimulates the transcription of N-acetylglucosaminyltransferase V and expression of its cell surface oligosaccharide products.
Chen L; Zhang W; Fregien N; Pierce M
Oncogene; 1998 Oct; 17(16):2087-93. PubMed ID: 9798679
[TBL] [Abstract][Full Text] [Related]
7. ERF: an ETS domain protein with strong transcriptional repressor activity, can suppress ets-associated tumorigenesis and is regulated by phosphorylation during cell cycle and mitogenic stimulation.
Sgouras DN; Athanasiou MA; Beal GJ; Fisher RJ; Blair DG; Mavrothalassitis GJ
EMBO J; 1995 Oct; 14(19):4781-93. PubMed ID: 7588608
[TBL] [Abstract][Full Text] [Related]
8. Mouse models in the study of the Ets family of transcription factors.
Bartel FO; Higuchi T; Spyropoulos DD
Oncogene; 2000 Dec; 19(55):6443-54. PubMed ID: 11175360
[TBL] [Abstract][Full Text] [Related]
9. ETS1 and ETS2 in p53 regulation: spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction.
Venanzoni MC; Robinson LR; Hodge DR; Kola I; Seth A
Oncogene; 1996 Mar; 12(6):1199-1204. PubMed ID: 8649821
[TBL] [Abstract][Full Text] [Related]
10. Ets2 and protein kinase C epsilon are important regulators of parathyroid hormone-related protein expression in MCF-7 breast cancer cells.
Lindemann RK; Braig M; Hauser CA; Nordheim A; Dittmer J
Biochem J; 2003 Jun; 372(Pt 3):787-97. PubMed ID: 12628005
[TBL] [Abstract][Full Text] [Related]
11. junB promoter regulation: Ras mediated transactivation by c-Ets-1 and c-Ets-2.
Coffer P; de Jonge M; Mettouchi A; Binetruy B; Ghysdael J; Kruijer W
Oncogene; 1994 Mar; 9(3):911-21. PubMed ID: 8108135
[TBL] [Abstract][Full Text] [Related]
12. Ets transcription factors and targets in osteogenesis.
Raouf A; Seth A
Oncogene; 2000 Dec; 19(55):6455-63. PubMed ID: 11175361
[TBL] [Abstract][Full Text] [Related]
13. Defective trophoblast function in mice with a targeted mutation of Ets2.
Yamamoto H; Flannery ML; Kupriyanov S; Pearce J; McKercher SR; Henkel GW; Maki RA; Werb Z; Oshima RG
Genes Dev; 1998 May; 12(9):1315-26. PubMed ID: 9573048
[TBL] [Abstract][Full Text] [Related]
14. ETS2 function is required to maintain the transformed state of human prostate cancer cells.
Sementchenko VI; Schweinfest CW; Papas TS; Watson DK
Oncogene; 1998 Dec; 17(22):2883-8. PubMed ID: 9879994
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA 17-92 cluster mediates ETS1 and ETS2-dependent RAS-oncogenic transformation.
Kabbout M; Dakhlallah D; Sharma S; Bronisz A; Srinivasan R; Piper M; Marsh CB; Ostrowski MC
PLoS One; 2014; 9(6):e100693. PubMed ID: 24968297
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic Ras can induce transcriptional activation through a variety of promoter elements, including tandem c-Ets-2 binding sites.
Galang CK; Der CJ; Hauser CA
Oncogene; 1994 Oct; 9(10):2913-21. PubMed ID: 8084596
[TBL] [Abstract][Full Text] [Related]
17. Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells.
Sapi E; Flick MB; Rodov S; Kacinski BM
Cancer Res; 1998 Mar; 58(5):1027-33. PubMed ID: 9500466
[TBL] [Abstract][Full Text] [Related]
18. Physical interaction and functional synergy between glucocorticoid receptor and Ets2 proteins for transcription activation of the rat cytochrome P-450c27 promoter.
Mullick J; Anandatheerthavarada HK; Amuthan G; Bhagwat SV; Biswas G; Camasamudram V; Bhat NK; Reddy SE; Rao V; Avadhani NG
J Biol Chem; 2001 May; 276(21):18007-17. PubMed ID: 11279115
[TBL] [Abstract][Full Text] [Related]
19. Role of Ets2 in cyclic AMP regulation of the human chorionic gonadotropin beta promoter.
Johnson W; Jameson JL
Mol Cell Endocrinol; 2000 Jul; 165(1-2):17-24. PubMed ID: 10940479
[TBL] [Abstract][Full Text] [Related]
20. Constitutive c-ets2 expression in M1D+ myeloblast leukemic cells induces their differentiation to macrophages.
Aperlo C; Pognonec P; Stanley ER; Boulukos KE
Mol Cell Biol; 1996 Dec; 16(12):6851-8. PubMed ID: 8943340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
